CIK 0001434647 · Non-accelerated filer<br>Smaller reporting company
ZEVRA THERAPEUTICS, INC.
Sign in to watch- Ticker
- ZVRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205894398
- Phone
- (888) 958-1253
- Business address
- 101 FEDERAL STREET, BOSTON, MA, 02110
- Former names
- KEMPHARM, INC, KEMPHARM INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $224,948
- in 1 filing, $225K under 10b5-1 plans
Net −$224,948. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-12 | McFarlane Neil F. President and CEO | Sale 10b5-1 | −20,000 | $11.25 | $225K | 417,225 |
| 2026-10-10 | McFarlane Neil F. President and CEO | Option exercise 10b5-1 | +50,000 | 437,225 | ||
| 2026-10-10 | McFarlane Neil F. President and CEO | Option exercise · Restricted Stock Unit 10b5-1 | −50,000 | 50,000 | ||
| 2026-08-14 | Thompson Rahsaan Chief Legal & Compliance | Sale 10b5-1 | −42,666 | $11.13 | $475K | 37,569 |
| 2026-08-10 | Watton Corey Michael Director | Option exercise | +12,300 | $4.97 | $61K | 14,100 |
| 2026-08-10 | Watton Corey Michael Director | Sale | −12,300 | $11.25 | $138K | 1,800 |
| 2026-08-10 | Watton Corey Michael Director | Option exercise · Stock Option (right to buy) | −12,300 | 46,500 | ||
| 2026-06-22 | Thompson Rahsaan Chief Legal & Compliance | Sale 10b5-1 | −34,557 | $12.68 | $438K | 80,235 |
| 2026-06-21 | Thompson Rahsaan Chief Legal & Compliance | Option exercise 10b5-1 | +66,667 | 114,792 | ||
| 2026-06-21 | Thompson Rahsaan Chief Legal & Compliance | Option exercise · Restricted Stock Unit 10b5-1 | −66,667 | 66,667 | ||
| 2026-06-04 | FAVORITO TAMARA A Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2026-06-04 | Secor Alicia Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2026-06-04 | Watton Corey Michael Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2026-06-04 | Calder Douglas W Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2026-06-04 | Anderson Thomas Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2026-06-04 | Shih Alvin Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2026-05-28 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2026-05-28 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Grant or award · Restricted Stock Unit | +20,000 | 20,000 | ||
| 2026-05-11 | Thompson Rahsaan Chief Legal & Compliance | Sale 10b5-1 | −1,794 | $11.30 | $20K | 48,125 |
| 2026-03-24 | Bode John B Director | Option exercise | +39,200 | $4.97 | $195K | 84,200 |
Page 1 of 9 · 166 trades